Posted: 6 month(s) and 28 days(s) ago   |   0 Comment(s)   |   Rating: 0 0
Posted by: ToddShriber

Quigley Corp. (QGLY.NSDQ), the drug delivery company that I mentioned a couple of weeks ago after a solid earnings report, fell 47 cents, or 17%, to $2.35 today, making the stock the top loser on the Nasdaq. Volume was right in line with the daily average.

There was no news impacting the stock today, but it is worth noting that big pharma stocks haven't really participated in the recent market rally, so it's hard to get bullish on smaller players like Quigley.

Looking at Quigley's chart, the stock failed miserably above $3 and will likely find support at a downward trendline that rests at $1.75. If the shares fell to that level and no further, then a bounce higher is possible. However, if Quigley violates $1.75, I'd stay away.

For more on Quigley, go here: http://www.quigleyco.com

Add Comment / Rating

Posted: 9 month(s) and 10 days(s) ago   |   0 Comment(s)   |   Rating: 0 0
Posted by: ToddShriber

Jazz Pharmaceuticals (JAZZ.NSDQ) surged $2.14, or 210%, to $3.16 ahead of a Phase III clinical data release for its fibromyalgia treatment candidate sodium oxybate, or JZP-6. The stock was the top gainer on the Nasdaq today as over 18 million shares changed hands compared to average daily volume of less than 58,000.

Jazz hopes to file for approval of the drug by the end of this year. Sodium oxybate is already used to treat sleep disorders, according to press reports.

The Street seems to be anticipating good news and Jazz will present findings later this week so the stock is worth a watch. Any more good news and the stock could definitely surge some more.

Add Comment / Rating

Posted: 9 month(s) and 11 days(s) ago   |   0 Comment(s)   |   Rating: 0 0
Posted by: ToddShriber

MDRNA (MRNA.NSDQ) shot up $1.16, or 75%, to $2.70 after the FDA approved the company's generic version of the osteoporosis treatment Miacalcin. The stock was the biggest gainer on the Nasdaq today.

MDRNA said U.S. sales of Miacalcin totaled $112 million in 2008. Novartis AG makes Miacalcin. MDRNA partners with Par Pharmaceuticals (PRX.NYSE) to make the generic Miacilin.

MDRNA shares had been languishing below $1 for most of 2009, so it will be interesting to see how the stock performs in light of today's news.

Add Comment / Rating